Tuberculin Skin Test Market Size is USD 2.88 Billion in 2026

The global Tuberculin Skin Test (TST) market was valued at USD 2.6 billion in 2025 and is projected to reach USD 7.12 billion by 2035, growing at a robust CAGR of 10.60%. This growth is driven by increasing tuberculosis (TB) prevalence, advancements in diagnostic technologies, and rising demand for early TB detection and treatment.

Tuberculin Skin Test Market Statical Scope

Market Overview

What is the Tuberculin Skin Test?

The tuberculin skin test market focuses on diagnostic solutions used to detect latent and active tuberculosis infections. It remains widely adopted due to its low cost, simplicity, and suitability for large-scale screening programs. Demand is driven by the high global burden of tuberculosis and strong public health initiatives aimed at early detection and disease control. The market is especially prominent in developing regions where access to advanced diagnostic tools is limited.

Tuberculin Skin Test Market, By Region

• Asia Pacific: Leading market due to its high tuberculosis burden and large population base.
• North America: The market is driven by ongoing public health efforts to detect and control tuberculosis, particularly in high-risk populations
• Europe: Remains active as public health authorities continue screening in at-risk groups, including migrants, healthcare workers, and immunocompromised individuals.
• Latin America: Expanding as countries strengthen tuberculosis screening and control efforts amid persistent TB incidences.
• Middle East & Africa: Growing as governments and health agencies intensify tuberculosis screening efforts in regions with high TB prevalence.

Segment Insights

Tuberculin Skin Test Market, By Diagnostic Test Type

• Smear Microscopy: Detects tuberculosis by examining sputum samples under a microscope for the presence of Mycobacterium tuberculosis bacteria.
• Culture-Based Tests: Grow and identify TB bacteria from patient samples, providing highly accurate detection and confirmation of infection.
• Nucleic Acid Testing: Uses molecular techniques like PCR to detect TB DNA quickly and with high sensitivity.
• Mantoux Test (Tuberculin Skin Test): Measures the body's immune response to injected tuberculin to indicate latent or active TB infection.
• Radiography: Visualizes lung abnormalities and lesions associated with active tuberculosis infection.
• Drug Susceptibility Testing (DST): Determines whether TB bacteria are resistant or sensitive to specific anti-tuberculosis drugs to guide treatment.

Tuberculin Skin Test Market, By End User

• Hospitals: Use tuberculin skin tests for routine screening of patients, especially high-risk and immunocompromised individuals.
• Clinics: Offer TB testing for outpatient care, community health programs, and preventive screenings.
• Laboratories: Conduct tuberculin skin test analysis and complementary diagnostic tests to confirm TB identification.
• Academics and Research: Utilize the test in studies to develop new diagnostics, treatments, and epidemiological research on tuberculosis.

Tuberculin Skin Test Market Share, By Region, 2025 (%)

• North America (25%) — Established market with advanced healthcare infrastructure and extensive tuberculosis control programs.
• Europe (35%) — Leading region for tuberculosis diagnostics due to strong healthcare systems, extensive research, and a diverse population.
• Asia Pacific (30%) — A rapidly growing market due to the high burden of tuberculosis cases and expanding diagnostic infrastructure.
• LAMEA (10%) — Developing region with increasing access to tuberculosis diagnostic tests, but lower market penetration compared to other regions.

Tuberculin Skin Test Market Share, By Type, 2025 (%)

• Smear Microscopy (15%) — A traditional method using stained sputum samples to visually identify Mycobacterium tuberculosis under a microscope.
• Culture-Based Tests (18%) — Laboratory tests that grow tuberculosis bacteria from samples to confirm the infection and determine drug resistance.
• Nucleic Acid Testing (12%) — Molecular diagnostic tests that detect Mycobacterium tuberculosis genetic material in patient samples for faster diagnosis.
• Mantoux Test (30%) — A skin test that involves injecting a small amount of tuberculin to test for a previous or current tuberculosis infection.
• Radiography (13%) — Imaging technique using X-rays to detect lung abnormalities indicative of tuberculosis infection.
• Drug Susceptibility Testing (7%) — Tests used to determine the effectiveness of tuberculosis drugs on bacterial strains.
• Other Tests (5%) — Additional diagnostic methods used in specific cases of tuberculosis detection.

Tuberculin Skin Test Market Share, By End User, 2025 (%)

• Hospitals (45%) — Healthcare facilities providing diagnostic and treatment services for tuberculosis, including advanced testing and care.
• Clinics (25%) — Medical establishments focused on diagnosing and managing tuberculosis in outpatient settings.
• Laboratories (15%) — Specialized facilities conducting tuberculosis testing, including culture, nucleic acid testing, and drug resistance profiling.
• Academics and Research (10%) — Institutions conducting research and clinical trials related to tuberculosis diagnostics and treatments.
• Others (5%) — Various non-traditional settings such as public health departments or mobile units contributing to tuberculosis diagnosis.

Tuberculin Skin Test Market Companies

• Abbott Laboratories, Inc.
• Akonni Biosystems, Inc.
• Beckton, Dickinson and Company
• bioMerieux SA
• Cepheid, Inc.
• Epistem Holdings plc
• Hain Lifescience GmbH
• Hologic, Inc.
• Qiagen N.V.
• Roche Holding AG (F. Hoffmann-La Roche AG)
• Sanofi S.A.
• Thermo Fisher Scientific, Inc.

Tuberculin Skin Test Market Segmentation

By Diagnostic Test Type

• Smear Microscopy
• Culture Based Tests
• Nucleic Acid Testing
• Mantoux Test 
• Radiography 
• Drug Susceptibility Testing 
• Other Tests 

By End User

• Hospitals
• Clinics
• Laboratories
• Academics and Research
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA